Abdominal Binder in Colonoscopies Performed by Trainees

Use of Abdominal Binder in Colonoscopies Performed by Trainees in Gastrointestinal Endoscopy: A Randomized, Double-blind, Sham-controlled Trial

This randomized trial will be conducted to evaluate the effectiveness and safety of an abdominal binder use during colonoscopy performed by gastrointestinal endoscopy fellow trainees. The investigators hypothesized that the abdominal binder use would facilitate and increase the effectiveness of the colonoscopy for inexperienced operators.

Study Overview

• Status: Completed
• Conditions: Performance of Colonoscopy; Tolerance of Colonoscopy
• Intervention / Treatment: Device: Abdominal binder (Revive 3-in-1 Postpartum Recovery Support Belt); Device: Loose abdominal binder (Revive 3-in-1 Postpartum Recovery Support Belt)

Detailed Description

It will be a randomized, double-blind, sham-controlled study. The trial will be performed at a single-center, Hospital Central Norte PEMEX, a tertiary center with a gastrointestinal endoscopy fellow trainee program with more than 10 years of experience. This trial will be conducted in accordance with the most recent version of the Declaration of Helsinki. The trial has been approved by the local ethical committee and research committee with the number DCAS-SSS GSM-HCN-INV-0043-2022. Written informed consent will be obtained from all the patients before participation. This manuscript will be reported in accordance with CONSORT guidelines.

Prior to the procedure, age, sex, height, weight, waist circumference (WC), body mass index (BMI), and colonoscopy indication of all participants will be recorded. Once enrolled, patients will be randomized to either the abdominal binder (AB) group or the sham binder (SB) group in a 1:1 ratio. Randomization will be performed using a web-based computer system (Research Randomizer, Geoffrey C. Urbaniak and Scott Plous) by an independent statistician who had no other intervention in the study. An independent operator will print the randomization number and group for each participant (either the AB or SB group) in individual cards, which will be hidden in a locked black box by the same independent operator. Only the nurse, who will fit the abdominal binder to all the patients in a private space, will have access to the cards. Randomized data and cards will be concealed to study coordinators, endoscopists, clinical staff, and participants.

The abdominal binder to be used for the patients allocated in the AB group was the Revive 3-in-1 Postpartum Recovery Support Belt (KeaBabies® Co., CA, USA). Its price is $29.96. The device is manufactured in two sizes, One Size and X-Large. For the patients with a waist circumference >110 cm it will be used the X-Large model. The three belts that make up the binder will be fitted to all the participants. Once placed, the binder will be adjusted to be located between the subcostal border and the anterior superior iliac spine. The participants will be asked to confirm that the binder is fastened tightly but not uncomfortably. For the participants in the SB group the same binder will be fitted, but once the patient is sedated, it will be loosened by the same nurse. The participants will wear a non-transparent gown over the binder so that it will not be visible to the endoscopists.

Bowel preparation with 4 L of polyethylene glycol solution in split-dose (2 L in the afternoon of the day before and 5 h before the colonoscopy) will be used in all the participants. In this trial, all colonoscopy procedures will be performed by two second-year fellow trainees in gastrointestinal endoscopy.

A standard video-colonoscope (EC-3890Li, PENTAX Co., Tokyo, Japan) will be used. All the patients will be placed in the left lateral decubitus position. Manual abdominal compression and postural change will be conducted by a technician when required by the endoscopy trainee or the attending endoscopist. Endoscopist or anesthesiology will be allowed to remove the binder at any time during the procedure if they resolve it was necessary for safety. Air insufflation will be used during colonoscopy.

Sample size was estimated over the primary outcome of the study based on pre-experimental data estimation and previously reported CIT and SD of similar studies with fellows' participation. It was calculated that 142 participants were needed to detect a 60-second difference in CIT (SD 110 sec), with 90% power and two-side alpha 0.05. Moreover, it was also calculated based on the frequency of ancillary maneuvers, using pre-experimental data estimation and literature data. It was found that 186 participants (93 per group) were needed to detect a 20% reduction in the use of ancillary maneuvers, with 90% power and two-side alpha 0.05. As a preventive measure in case of withdrawal or exclusion, the sample was expanded by 10%, a total of 206 patients, 103 in each group were included in the study.

Descriptive statistical analysis, including mean, mode, and frequencies will be performed for the description of the study data. The comparative analysis of the quantitative data will be previously subjected to normality evaluation by the Shapiro-Wilk test and graphical analyses. According to the normality, data comparative analysis will be performed either with a two-way Student's test or U Mann-Whitney test. For the comparative analyses of the categorical data (e.g., manual abdominal compression, postural change, need for intervention by the attending endoscopist) will be used chi-square or Fisher' exact test. A p value of <0.05 will be accepted as statistical significance. Statistical inferential analysis will be performed using RStudio® (R Core Team v.1.2.5033; R Foundation for Statistical Computing, Vienna, Austria) and SPSS® Statistics for Windows Version 23.0 (IBM Corp., Armonk, NY, USA). RStudio® (R Core Team v.1.2.5033) will be also used for drawing graphics. The study biostatistician (SA) will be blinded to the randomization phase and recollection data process.

• Study Type: Interventional
• Enrollment (Actual): 211
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Mexico
  • Mexico city, Mexico, 02720
    • Antonio Marmolejo

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 20 years to 80 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Male and female adults between the ages of 20-80
• Participants with ASA I-III (American Society of Anesthesiologists Class)
• Undergoing a colonoscopy at any of the study locations for:

I. CRC screening (first colonoscopy or 10 years follow up of negative exam). II. Surveillance (prior colonoscopy with polyps). III. Diagnostic colonoscopy performed to evaluate symptoms such as abdominal pain or rectal bleeding.

- Participants must have completed the full prescribed colonoscopy purgative preparation prior to their procedure and describe adequate cleansing.

Exclusion Criteria:

• Inability to provide informed consent.
• Patients with known or suspected pregnancy.
• Patients undergoing multiple procedures (e.g., upper and lower endoscopy).
• Previous colon resection surgery.
• History of problems with sedation or anesthesia.
• Patients with known or suspected diagnosis of inflammatory bowel disease (ulcerative colitis or Crohn's disease).
• Patients with a history of colorectal cancer or other intra-abdominal malignancy.
• Patients with open or recent wounds or skin rash on the anterior abdominal wall.
• History of cirrhosis or ascites.
• Patients who are medically unstable (American Society of Anesthesiology Class IV or above).

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Abdominal Binder Intervention Group; Patients randomized to the Abdominal Binder Intervention Group will have the abdominal binder (Revive 3-in-1 Postpartum Recovery Support Belt) secured firmly between the subcostal border and the anterior superior iliac spine area to the abdomen just prior the colonoscopy.	Device: Abdominal binder (Revive 3-in-1 Postpartum Recovery Support Belt); Revive 3-in-1 Postpartum Recovery Support Belt (KeaBabies® Co., CA, USA). An abdominal binder is a kind of elastic abdominal compression device; Other Names: Revive 3-in-1 Postpartum Recovery Support Belt (KeaBabies® Co., CA, USA); Revive 3-in-1 abdominal binder
Sham Comparator: Sham Group; Sham Group will have the abdominal binder (Revive 3-in-1 Postpartum Recovery Support Belt) secured firmly between the subcostal border and the anterior superior iliac spine area to the abdomen just prior the colonoscopy but it will be loosened just prior the procedure.	Device: Loose abdominal binder (Revive 3-in-1 Postpartum Recovery Support Belt); Revive 3-in-1 Postpartum Recovery Support Belt (KeaBabies® Co., CA, USA). An abdominal binder is a kind of elastic abdominal compression device. It will be loosened just prior the procedure.; Other Names: Revive 3-in-1 Postpartum Recovery Support Belt (KeaBabies® Co., CA, USA); Revive 3-in-1 abdominal binder

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Mean Cecal Intubation Time	Cecal intubation time will be defined as the time from insertion of the colonoscope into the rectum to identification of the base of the cecum	During colonoscopy, from insertion of scope into rectum to point in time when base of the cecum is identified, an average of 30 minutes.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Frequency of Use of Abdominal Pressure	Binary data indicating individually when the abdominal pressure was used during the insertion phase of the procedure will be recorded.	During colonoscopy, from insertion of scope into rectum to point in time when base of the cecum is identified, an average of 30 minutes.
Length of Cecal Intubation	The length of the colonoscope required to reach de cecum from the anus will be measured.	During colonoscopy, from insertion of scope into rectum to point in time when base of the cecum is identified, an average of 30 minutes.
Frequency of Intervention by the Attending Endoscopist	Binary data indicating individually if intervention by the attending endoscopist was required during the insertion phase of the procedure will be recorded.	During colonoscopy, from insertion of scope into rectum to point in time when base of the cecum is identified, an average of 30 minutes.
Colonoscopy Completion Rate	Dichotomous outcome indicating if the procedure was complete.	During colonoscopy, from insertion of scope into rectum to point in time when base of the cecum is identified, an average of 30 minutes.
Number of Participants With Mild, Moderate, and Severe Procedural Difficulty as Assessed by Trainees	Immediately following completion of procedure, the study assistant will obtain the trainee's assessment of procedural difficulty according to three grades of severity: mild, moderate, and severe. *We found the 5-point scale more difficult to use in the dynamic of the endoscopy room. The Operator's Assessment of Procedural Difficulty scale was not used. The difficulty was rated as mild when the colonoscope was smoothly inserted, moderate when there were some difficulties quickly solved (less than 60 seconds), and severe when the difficulties were more difficult requiring a longer time (more than 60 seconds).	Immediately following completion of procedure when scope is removed from rectum, an average of 10 minutes after completion of the procedure.
Number of Participants According to Colonoscopy Findings	Findings such as polyps, cancer, diverticulum, and IBD (inflammatory bowel disease) detected during colonoscopy will be recorded.	During colonoscopy, from insertion of scope into rectum to point in time when base of the cecum is identified, an average of 30 minutes.
Operator Perception of Patient Discomfort	Immediately following completion of procedure, the study assistant will obtain operator's perception of patient discomfort during procedure according to the Gloucester score. The Gloucester score will be used. It is a comfort grading scale ranging from 1 to 5 points, with 1 point if no discomfort is present during the colonoscopy and 5 if there is extreme discomfort during the colonoscopy.	Immediately following completion of procedure when scope is removed from rectum, an average of 10 minutes after completion of the procedure.
Additional Analgesic Drug Required to Complete Procedure	Whether the patient needs an additional dose of analgesic drug to complete the colonoscopy.	During colonoscopy, from time point of insertion of scope into de rectum to point in time when scope is removed from rectum, an average of 30 minutes.
Patient Pain at Discharge	The study assistant will interview patient just prior to discharge and obtain responses for pain according to a 10-point visual analog scale. The Visual analogue scale (VAS) will be used. It is a pain grading scale ranging from 0 to 10 points, with 0 if no pain and 10 if worst pain possible.	At single time point occurring after the colonoscopy, just prior to the patient being discharged from facility, an average of 90 minutes after completion of the procedure.
Patient Satisfaction at Discharge	The study assistant will interview patient just prior to discharge and obtain responses for satisfaction according to a 5-point Likert scale. The Satisfaction Likert scale will be used. It is a satisfaction grading scale ranging from 1 to 5 points, with 1 if very poor satisfaction and 5 if excellent satisfaction.	At single time point occurring after the colonoscopy, just prior to the patient being discharged from facility, an average of 90 minutes after completion of the procedure.
Frequency of Use of Position Change	Binary data indicating when the patient position change was used during the insertion phase of the procedure will be recorded.	During colonoscopy, from insertion of scope into rectum to point in time when base of the cecum is identified, an average of 30 minutes.
Additional Anesthetic Drug Required to Complete Procedure	Whether the patient needs an additional dose of anesthetic drug to complete the colonoscopy.	During colonoscopy, from time point of insertion of scope into de rectum to point in time when scope is removed from rectum, an average of 30 minutes.

Collaborators and Investigators

• Sponsor: Hospital Central Norte PEMEX
• Investigators: Study Chair: Monica Arellano, M.D, Ethical committee president of the Hospital Central Norte PEMEX

Publications and helpful links

General Publications

• Rex DK, Schoenfeld PS, Cohen J, Pike IM, Adler DG, Fennerty MB, Lieb JG 2nd, Park WG, Rizk MK, Sawhney MS, Shaheen NJ, Wani S, Weinberg DS. Quality indicators for colonoscopy. Gastrointest Endosc. 2015 Jan;81(1):31-53. doi: 10.1016/j.gie.2014.07.058. Epub 2014 Dec 2. No abstract available.
• Toyoshima O, Nishizawa T, Sakitani K, Yamakawa T, Yoshida S, Fukagawa K, Hata K, Ishihara S, Suzuki H. Colonoscopy using back brace support belt: A randomized, prospective trial. JGH Open. 2019 Nov 7;4(3):441-445. doi: 10.1002/jgh3.12276. eCollection 2020 Jun.
• Crockett SD, Cirri HO, Kelapure R, Galanko JA, Martin CF, Dellon ES. Use of an Abdominal Compression Device in Colonoscopy: A Randomized, Sham-Controlled Trial. Clin Gastroenterol Hepatol. 2016 Jun;14(6):850-857.e3. doi: 10.1016/j.cgh.2015.12.039. Epub 2016 Jan 6.

Study record dates

Study Major Dates

• Study Start (Actual): November 15, 2022
• Primary Completion (Actual): January 25, 2023
• Study Completion (Actual): January 28, 2023

Study Registration Dates

• First Submitted: September 15, 2022
• First Submitted That Met QC Criteria: November 14, 2022
• First Posted (Actual): November 15, 2022

Study Record Updates

• Last Update Posted (Actual): May 1, 2024
• Last Update Submitted That Met QC Criteria: April 26, 2024
• Last Verified: April 1, 2024

More Information

Terms related to this study

• Keywords: colonoscopy; abdominal binder; looping
• Additional Relevant MeSH Terms: Physiological Effects of Drugs; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Purinergic Antagonists; Purinergic Agents; Phosphodiesterase Inhibitors; Purinergic P1 Receptor Antagonists; Central Nervous System Stimulants; Caffeine
• Other Study ID Numbers: DCAS-SSS GSM-HCN-INV-0043-2022

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: all IPD that underlie results in a publication
• IPD Sharing Time Frame: Starting 6 months after publication
• IPD Sharing Access Criteria: Formal requests for IPD information should be made by email (dr.marmolejo.ch@gmail.com) to the principal investigator Antonio Marmolejo
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; ICF; CSR

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No